Guardant Health Grants Co-CEOs 465,413 Performance-Based Stock Units Each at Target

By Public Technologies13:20 (UTC), 3 November 2026 Updated

Guardant Health granted co-CEOs Helmy Eltoukhy and AmirAli Talasaz 465,413 target performance-based restricted stock units each on November 2, 2026.
Performance periods begin June 1, 2026; 25% runs through May 31, 2029, with 75% through May 31, 2031.
Payouts require S&P 500-relative shareholder returns reaching the 40th percentile; target requires the 55th percentile, with 250% earned at the 90th percentile.
Negative absolute total shareholder returns cap payouts at 100% of target; vesting generally requires continued service through performance certification.
Three-year award shares generally face holding restrictions through May 31, 2030; restrictions cover half of five-year net after-tax shares through November 30, 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-444416), on November 03, 2026, and is solely responsible for the information contained therein.